Imidapril

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Summary

Imidapril is an ACE inhibitor used in the treatment of essential hypertension.

Generic Name
Imidapril
DrugBank Accession Number
DB11783
Background

Imidapril has been investigated for the treatment of Kidney, Polycystic, Autosomal Dominant.

Type
Small Molecule
Groups
Investigational
Structure
Thumb
Weight
Average: 405.4449
Monoisotopic: 405.189985611
Chemical Formula
C20H27N3O6
Synonyms
  • Imidapril

Pharmacology

Indication

Not Available

Pharmacology
Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Associated Conditions
Contraindications & Blackbox Warnings
Contraindications
Avoid life-threatening adverse drug events
Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Adverseeffects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AcebutololAcebutolol may increase the hypotensive activities of Imidapril.
AceclofenacThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Aceclofenac is combined with Imidapril.
AcemetacinThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Acemetacin is combined with Imidapril.
Acetylsalicylic acidThe therapeutic efficacy of Imidapril can be decreased when used in combination with Acetylsalicylic acid.
Agrostis gigantea pollenThe risk or severity of adverse effects can be increased when Imidapril is combined with Agrostis gigantea pollen.
Agrostis stolonifera pollenThe risk or severity of adverse effects can be increased when Imidapril is combined with Agrostis stolonifera pollen.
AlclofenacThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Alclofenac is combined with Imidapril.
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Imidapril.
AlfentanilAlfentanil may decrease the antihypertensive activities of Imidapril.
AlfuzosinAlfuzosin may increase the hypotensive activities of Imidapril.
Interactions
Identify potential medication risks
Easily compare up to 40 drugs with our drug interaction checker.
Get severity rating, description, and management advice.
Learn more
Food Interactions
Not Available

Products

Products2
Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
Product Ingredients
IngredientUNIICASInChI Key
Imidapril hydrochloride7NSF9GG1NU89396-94-1LSLQGMMMRMDXHN-GEUPQXMHSA-N

Categories

ATC Codes
C09AA16 — Imidapril
Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as dipeptides. These are organic compounds containing a sequence of exactly two alpha-amino acids joined by a peptide bond.
Kingdom
Organic compounds
Super Class
Organic acids and derivatives
Class
Carboxylic acids and derivatives
Sub Class
Amino acids, peptides, and analogues
Direct Parent
Dipeptides
Alternative Parents
Alpha amino acid esters / N-acyl-L-alpha-amino acids / Alpha amino acid amides / N-acyl ureas / Fatty acid esters / Aralkylamines / Imidazolidinones / Dicarboxylic acids and derivatives / Benzene and substituted derivatives / Dicarboximides
show 9 more
Substituents
Alpha-amino acid amide / Alpha-amino acid ester / Alpha-amino acid or derivatives / Alpha-dipeptide / Amine / Amino acid / Amino acid or derivatives / Aralkylamine / Aromatic heteromonocyclic compound / Azacycle
show 26 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
Not Available
Affected organisms
Not Available

Chemical Identifiers

UNII
BW7H1TJS22
CAS number
89371-37-9
InChI Key
KLZWOWYOHUKJIG-BPUTZDHNSA-N
InChI
InChI=1S/C20H27N3O6/c1-4-29-19(27)15(11-10-14-8-6-5-7-9-14)21-13(2)17(24)23-16(18(25)26)12-22(3)20(23)28/h5-9,13,15-16,21H,4,10-12H2,1-3H3,(H,25,26)/t13-,15-,16-/m0/s1
IUPAC Name
(4S)-3-[(2S)-2-{[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino}propanoyl]-1-methyl-2-oxoimidazolidine-4-carboxylic acid
SMILES
[H][C@@](C)(N[C@@]([H])(CCC1=CC=CC=C1)C(=O)OCC)C(=O)N1C(=O)N(C)C[C@@]1([H])C(O)=O

References

General References
  1. BPOM Drug Information: Imidapril monograph [Link]
  2. TITCK Product Information: Tanatril (imidapril hydrochloride) oral tablets [Link]
Human Metabolome Database
HMDB0041907
PubChem Compound
5464343
PubChem Substance
347828133
ChemSpider
4576628
BindingDB
50020400
RxNav
60245
ChEBI
135654
ChEMBL
CHEMBL317094
ZINC
ZINC000003784427
PharmGKB
PA452640
Wikipedia
Imidapril

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
3Unknown StatusTreatmentHigh Blood Pressure (Hypertension) / Microalbuminuria / Type 2 Diabetes Mellitus1
3Unknown StatusTreatmentHypertension, Essential Hypertension1
2Unknown StatusTreatmentAutosomal Dominant Polycystic Kidney Disease (ADPKD)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
PowderOral
TabletOral
TabletOral10 MG
TabletOral20 mg
TabletOral5 MG
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.447 mg/mLALOGPS
logP0.74ALOGPS
logP-0.23ChemAxon
logS-3ALOGPS
pKa (Strongest Acidic)3.49ChemAxon
pKa (Strongest Basic)5.22ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count6ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area116.25 Å2ChemAxon
Rotatable Bond Count10ChemAxon
Refractivity103.2 m3·mol-1ChemAxon
Polarizability42.29 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Drug created on October 20, 2016 20:47 / Updated on May 14, 2021 01:12